Group One Trading
ELVN icon

Group One Trading’s Enliven Therapeutics ELVN Stock Holding History

Group One Trading’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78K Buy
+35
New +$1.49K ﹤0.01% 7062
2025
Q4 		– Sell
-34
Closed -$696 – 8374
2025
Q3 		$696 Buy
+34
New +$685 ﹤0.01% 8108
2022
Q4 		– Sell
-23,249
Closed -$372K – 7441
2022
Q3 		$212K Buy
+23,249
New +$137K ﹤0.01% 4085

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Group One Trading's ELVN Position: Q2 2026 in Review

Group One Trading opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 35 shares worth $1.78K. The stake represents ﹤0.01% of the portfolio and ranks #7062 among its holdings. This is a return to the name: Group One Trading previously reported a position in ELVN as recently as Q3 2025.

Group One Trading first reported a position in ELVN in Q3 2022 and has held it in 3 quarters since. The position peaked at $212K in Q3 2022. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Group One Trading held 35 shares of Enliven Therapeutics worth $1.78K as of Q2 2026.
  • Enliven Therapeutics was a new Group One Trading position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7062 holding.
  • Group One Trading first reported a position in Enliven Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • Group One Trading's Enliven Therapeutics position peaked at $212K in Q3 2022.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.